Collagen type VI is a subepithelial extracellular matrix component in airways and an adhesive substrate for oral pathogens [Bober et al.: J Innate Immun 2010;2:160–166]. Here, we report that collagen VI displays a dose-dependent antimicrobial activity against group A, C, and G streptococci by membrane disruption in physiological conditions. The data disclose previously unrecognized aspects of the extracellular matrix in innate host defense.

Keywords:
Antimicrobial activity, Innate host defense, Collagen type VI, Extracellular matrix, Streptococcus, Oral pathogens
1.
Bober M, Enochsson C, Collin M, Mörgelin M: Collagen VI is a subepithelial adhesive target for human respiratory tract pathogens. J Innate Immun 2010;2:160–166.
2.
Gara SK, Grumati P, Squarzoni S, Sabatelli P, Urciuolo A, Bonaldo P, Paulsson M, Wagener R: Differential and restricted expression of novel collagen VI chains in mouse. Matrix Biol 2011;30:248–257.
3.
Tooley LD, Zamurs LK, Beecher N, Baker NL, Peat RA, Adams NE, Bateman JF, North KN, Baldock C, Lamandé SR: Collagen VI microfibril formation is abolished by an {alpha}2(VI) von Willebrand factor type A domain mutation in a patient with Ullrich congenital muscular dystrophy. J Biol Chem 2010;285:33567–33576.
4.
Fitzgerald J, Rich C, Zhou FH, Hansen U: Three novel collagen VI chains, alpha4(VI), alpha5(VI), and alpha6(VI). J Biol Chem 2008;283:20170–20180.
5.
Specks U, Mayer U, Nischt R, Spissinger T, Mann K, Timpl R, Engel J, Chu ML: Structure of recombinant N-terminal globule of type VI collagen alpha 3 chain and its binding to heparin and hyaluronan. EMBO J 1992;11:4281–4290.
6.
Andersson E, Rydengård V, Sonesson A, Mörgelin M, Björck, L, Schmidtchen A: Antimicrobial activities of heparin-binding peptides. Eur J Biochem 2004;271:1219–1226.
7.
Oehmcke S, Shannon O, Mörgelin M, Herwald H: Streptococcal M proteins and their role as virulence determinants. Clin Chim Acta 2010;411:1172–1180.
8.
Oster HR, Bisno AL: Group C and Group G streptococcal infections: epidemiologic and clinical aspects; in Fischetti VA, Novik RP, Ferretti JJ, Portnoy DA, Rood JI (eds): The Gram-Positive Pathogens. Washington, American Society for Microbiology, 2000, pp 184–190.
9.
Haidan A, Talay SR, Rohde M, Sriprakash KS, Currie BJ, Chhatwal GS: Pharyngeal carriage of group C and group G streptococci and acute rheumatic fever in an Aboriginal population. Lancet 2000;356:1167–1169.
10.
Dinkla K, Rohde M, Jansen WT, Carapetis JR, Chhatwal GS, Talay SR: Streptococcus pyogenes recruits collagen via surface-bound fibronectin: a novel colonization and immune evasion mechanism. Mol Microbiol 2003;47:861–869.
11.
Patti JM, Allen BL, McGavin MJ, Höök M: MSCRAMM-mediated adherence of microorganisms to host tissues. Annu Rev Microbiol 1994;48:585–617.
12.
Nitsche DP, Johansson HM, Frick IM, Mörgelin M: Streptococcal protein FOG, a novel matrix adhesin interacting with collagen I in vivo. J Biol Chem 2006;281:1670–1679.
13.
Hallström T, Singh B, Resman F, M Blom A, Mörgelin M, Riesbeck K: Haemophilus influenzae protein E binds to the extracellular matrix by concurrently interacting with laminin and vitronectin. J Infect Dis 2011;204:1065–1074.
14.
Kihlberg BM, Collin M, Olsén A, Björck L: Protein H, an antiphagocytic surface protein in Streptococcus pyogenes. Infect Immun 1999;67:1708–1714.
15.
Mjörner H, Albertsson PÅ, Kronwall G: Isoelectric points and surface hydrophobicity of gram-positive cocci as determined by cross-partition and hydrophobic affinity partition in aqueous two-phase systems. Infect Immun 1982;36:227–234.
16.
Kronwall G, Myhre EB, Björck L, Berggård I: Binding of aggregated human β2-microglobulin to surface protein structure in group A, C and G streptococci. Infect Immun 1978;22:136–142.
17.
Widebäck K, Seal US, Kronwall G: Receptor in group C and G streptococci detects albumin structures present in mammalian species. Infect Immun 1982;36:469–475.
18.
Spissinger T, Engel J: Type VI collagen beaded microfibrils from bovine cornea depolymerize at acidic pH, and depolymerization and polymerization are not influenced by hyaluronan. Matrix Biol 1995;14:499–505.
19.
Oehmcke S, Mörgelin M, Herwald H: Activation of the human contact system on neutrophil extracellular traps. J Innate Immun 2009;1:225–230.
20.
Sörensen OE, Follin P, Johnsen AH, Calafat J, Tjabranga GS, Hiemstra PS, Borregaard N: Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001;97:3951–3959.
21.
Brennan EP, Reing J, Chew D, Myers-Irvin JM, Young EJ, Badylak SF: Antibacterial activity within degradation products of biological scaffolds composed of extracellular matrix. Tissue Eng 2006;12:2949–2955.
22.
Senyürek I, Klein G, Kalbacher H, Deeg M, Schittek B: Peptides derived from the human laminin a4 and a5 chains exhibit antimicrobial activity. Peptides 2010;31:1468–1472.
23.
Malmsten M, Davoudi M, Schmidtchen A: Bacterial killing by heparin-binding peptides from PRELP and thrombospondin. Matrix Biol 2006;25:294–300.
24.
Malmsten M, Davoudi M, Walse B, Rydengård V, Pasupuleti M, Mörgelin M, Schmidtchen A: Antimicrobial peptides derived from growth factors. Growth Factors 2007;25:60–70.
25.
Malmström E, Mörgelin M, Malmsten M, Johansson L, Norrby-Teglund A, Shannon O, Schmidtchen A, Meijers JC, Herwald H: Protein C inhibitor – a novel antimicrobial agent. PLoS Pathog 2009;5:e1000698.
26.
Kasetty G, Papareddy P, Kalle M, Rydengård V, Mörgelin M, Albiger B, Malmsten M, Schmidtchen A: The C-terminal sequence of several human serine proteases encodes host defense functions. J Innate Immun 2011;3:471–482.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.